Current status23 May 2026 10:40
Tate's Fresh Results Give Huber the Upper Hand - Tate & Lyle recently published full-year results, and the figures are a double-edged sword that actually helps Huber demand more money.
The Bad News: Revenue slipped 3% and adjusted pre-tax profit fell 5% to £238 million. This proves the standalone business is in a temporary cyclical rut, meaning the board cannot simply act bulletproof.
The Ace up the Sleeve: Tate revealed that the integration of CP Kelco (the asset they bought from Huber) is going incredibly well. They hit their annual $50 million cost-synergy target a full year ahead of schedule. Furthermore, the value of their cross-selling product pipeline more than doubled in the second half of the year.Huber can point directly to this data room evidence and say: "Look at how fast we are extracting value from CP Kelco. We aren't giving you this momentum for 615p.
The Pricing Gap: The City widely views 615p as an opening bid designed to get the doors unlocked. Because a UK Scheme of Arrangement requires 75% shareholder approval, Huber’s ~16% block gives them immense leverage to dictate the final price.The "Dead Zone" (615p – 640p): Low probability of success. Huber took their shares at an implied value closer to 680p during the CP Kelco sale. They will not crystallize a clear loss during a macro dip.The Sweet Spot (660p – 680p): High probability of an agreement. This allows Huber to break even or claim a minor win on their initial entry price, gives other institutional investors (like Lindsell Train) a near-80% premium on the undisturbed price, and stays within Ingredion's comfortable $3.3\times$ debt-leverage capacity